A Multimodal Treatment Strategy to Manage Severe Cutaneous Mpox
A 33-year-old bisexual man with advanced HIV and severe mpox developed severe cutaneous disease despite receiving tecovirimat, antiretroviral therapy, and vaccinia immune globulin. His condition improved after he received topical, intralesional, and intravenous cidofovir and debridement of his mpox...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
American College of Physicians
2024-12-01
|
| Series: | Annals of Internal Medicine: Clinical Cases |
| Online Access: | https://www.acpjournals.org/doi/10.7326/aimcc.2024.0282 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850146779698298880 |
|---|---|
| author | Navin Bhatt John Winters Yusra Shah Victoria E. Ruiz Ofole Mgbako Marcia Wong Madeline A. DiLorenzo |
| author_facet | Navin Bhatt John Winters Yusra Shah Victoria E. Ruiz Ofole Mgbako Marcia Wong Madeline A. DiLorenzo |
| author_sort | Navin Bhatt |
| collection | DOAJ |
| description | A 33-year-old bisexual man with advanced HIV and severe mpox developed severe cutaneous disease despite receiving tecovirimat, antiretroviral therapy, and vaccinia immune globulin. His condition improved after he received topical, intralesional, and intravenous cidofovir and debridement of his mpox lesions, but he required a 7-month hospitalization. His treatment was complicated by acute kidney injury secondary to cidofovir, so his antiretroviral therapy was switched to brincidofovir to complete treatment. All his lesions eventually resolved, but he eventually developed stage IV chronic kidney disease, likely due to cidofovir-related nephrotoxicity. Further research should investigate how to best balance the efficacy of severe mpox treatment with secondary effects. |
| format | Article |
| id | doaj-art-930367a1b84d4b508e37b53969cfb3ec |
| institution | OA Journals |
| issn | 2767-7664 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | American College of Physicians |
| record_format | Article |
| series | Annals of Internal Medicine: Clinical Cases |
| spelling | doaj-art-930367a1b84d4b508e37b53969cfb3ec2025-08-20T02:27:45ZengAmerican College of PhysiciansAnnals of Internal Medicine: Clinical Cases2767-76642024-12-0131210.7326/aimcc.2024.0282A Multimodal Treatment Strategy to Manage Severe Cutaneous MpoxNavin Bhatt0John Winters1Yusra Shah2Victoria E. Ruiz3Ofole Mgbako4Marcia Wong5Madeline A. DiLorenzo61Department of Medicine, New York City Health + Hospitals/Elmhurst, Icahn School of Medicine at Mount Sinai, Elmhurst, New York2Division of Infectious Diseases, Department of Medicine, New York City Health + Hospitals/Elmhurst, New York, New York4Division of Infectious Diseases, Department of Medicine, New York City Health + Hospitals/Bellevue, New York, New York6New York City Department of Health and Mental Hygiene, New York, New York4Division of Infectious Diseases, Department of Medicine, New York City Health + Hospitals/Bellevue, New York, New York6New York City Department of Health and Mental Hygiene, New York, New York4Division of Infectious Diseases, Department of Medicine, New York City Health + Hospitals/Bellevue, New York, New YorkA 33-year-old bisexual man with advanced HIV and severe mpox developed severe cutaneous disease despite receiving tecovirimat, antiretroviral therapy, and vaccinia immune globulin. His condition improved after he received topical, intralesional, and intravenous cidofovir and debridement of his mpox lesions, but he required a 7-month hospitalization. His treatment was complicated by acute kidney injury secondary to cidofovir, so his antiretroviral therapy was switched to brincidofovir to complete treatment. All his lesions eventually resolved, but he eventually developed stage IV chronic kidney disease, likely due to cidofovir-related nephrotoxicity. Further research should investigate how to best balance the efficacy of severe mpox treatment with secondary effects.https://www.acpjournals.org/doi/10.7326/aimcc.2024.0282 |
| spellingShingle | Navin Bhatt John Winters Yusra Shah Victoria E. Ruiz Ofole Mgbako Marcia Wong Madeline A. DiLorenzo A Multimodal Treatment Strategy to Manage Severe Cutaneous Mpox Annals of Internal Medicine: Clinical Cases |
| title | A Multimodal Treatment Strategy to Manage Severe Cutaneous Mpox |
| title_full | A Multimodal Treatment Strategy to Manage Severe Cutaneous Mpox |
| title_fullStr | A Multimodal Treatment Strategy to Manage Severe Cutaneous Mpox |
| title_full_unstemmed | A Multimodal Treatment Strategy to Manage Severe Cutaneous Mpox |
| title_short | A Multimodal Treatment Strategy to Manage Severe Cutaneous Mpox |
| title_sort | multimodal treatment strategy to manage severe cutaneous mpox |
| url | https://www.acpjournals.org/doi/10.7326/aimcc.2024.0282 |
| work_keys_str_mv | AT navinbhatt amultimodaltreatmentstrategytomanageseverecutaneousmpox AT johnwinters amultimodaltreatmentstrategytomanageseverecutaneousmpox AT yusrashah amultimodaltreatmentstrategytomanageseverecutaneousmpox AT victoriaeruiz amultimodaltreatmentstrategytomanageseverecutaneousmpox AT ofolemgbako amultimodaltreatmentstrategytomanageseverecutaneousmpox AT marciawong amultimodaltreatmentstrategytomanageseverecutaneousmpox AT madelineadilorenzo amultimodaltreatmentstrategytomanageseverecutaneousmpox AT navinbhatt multimodaltreatmentstrategytomanageseverecutaneousmpox AT johnwinters multimodaltreatmentstrategytomanageseverecutaneousmpox AT yusrashah multimodaltreatmentstrategytomanageseverecutaneousmpox AT victoriaeruiz multimodaltreatmentstrategytomanageseverecutaneousmpox AT ofolemgbako multimodaltreatmentstrategytomanageseverecutaneousmpox AT marciawong multimodaltreatmentstrategytomanageseverecutaneousmpox AT madelineadilorenzo multimodaltreatmentstrategytomanageseverecutaneousmpox |